The tool - Mutation Annotation and Genome Interpretation (MAGI) - is a free open-source web application that enables users to search, visualise, and annotate large public cancer genetics datasets, including data from The Cancer Genome Atlas (TCGA) project, which catalogues genetic mutations responsible for cancer, using genome sequencing and bioinformatics.
"The main motivation for MAGI has been to reduce the computational burden required for researchers or doctors to explore and annotate cancer genomics data," said Max Leiserson, a PhD student at Brown University.
In addition to viewing TCGA data, the portal also allows users to upload their own data and compare their findings to those in the larger databases.
"Over the last decade, researchers working with TCGA have sequenced genes from thousands of tumours and dozens of cancer types in an effort to understand which mutations contribute to the development of cancer," said Ben Raphael, director of Brown University's Centre for Computational and Molecular Biology, who helped oversee the project.
More From This Section
By uploading their data to MAGI, researchers can leverage the large public datasets to help interpret their own data.
"In cancer genomics, there's real value in large sample sizes because mutations are diverse and spread all over the genome," Raphael said.
MAGI has data from TCGA already loaded. Users can search by cancer type, by individual genes, or by groups of genes.
The output offers several ways of visualising the search results, showing how often a given gene is mutated across samples and what types of mutations they were.
"But in the process, they might also be able say something about the public data. We thought - wouldn't it be great if users could record that information and share it?" Raphael said.
The MAGI project started as a means of looking at the output from algorithms that Raphael's lab develops.
Those algorithms comb through large genome datasets, helping to pick out the mutations that are important to cancer development and distinguishing them from benign mutations that are just along for the ride.
"We decided to develop a public portal for the cancer genomics research community," Raphael said.